» Articles » PMID: 32383003

Topical Delivery of 5-fluorouracil-loaded Carboxymethyl Chitosan Nanoparticles Using Microneedles for Keloid Treatment

Overview
Publisher Springer
Specialty Pharmacology
Date 2020 May 9
PMID 32383003
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Keloids are induced by skin injuries such as surgeries, skin piercings, burns, and trauma. The intra-lesional injection of 5-fluorouracil (5-FU) is a promising therapy to treat keloid. However, local 5-FU injections have caused several side effects such as pain at administration and hyperpigmentation. This study suggests a safer and more effective 5-FU delivery system. We used microneedles to treat keloid because this method has the feasibility of self-administration without pain. In this study, 5-FU-loaded carboxymethyl chitosan (CMC) nanoparticles were prepared and characterized by various analytical methods and then coated on stainless solid microneedles. The blank CMC nanoparticles caused an increase in cell viability on human normal fibroblasts to 150%. In particular, the 5-FU-loaded CMC nanoparticles showed a significant inhibitory effect on the human keloid fibroblast to 16%. The intercellular uptake of the 5-FU-loaded CMC nanoparticles was observed on both human normal and keloid fibroblasts by using a confocal microscope. In addition, it was found that the nanoparticles showed an inhibition of TGF-β1 by ELISA. For topical drug delivery, it was confirmed that the nanoparticles coated onto the microneedles were dissolved and diffused at the administration site in the porcine dorsal skin model. According to these results, the suggested microneedle-mediated drug delivery system not only inhibits the human keloid fibroblasts by delivering drugs effectively into the keloids but also has the feasibility to self-administer without pain. Therefore, this new system including 5-FU-loaded CMC nanoparticles and microneedles has the potential to treat keloid scars. Graphical abstract.

Citing Articles

New challenges in scar therapy: the novel scar therapy strategies based on nanotechnology.

Chen Z, Gao J, Li L Nanomedicine (Lond). 2024; 19(28):2413-2432.

PMID: 39325688 PMC: 11492664. DOI: 10.1080/17435889.2024.2401768.


Adipose stem cell exosomes promote mitochondrial autophagy through the PI3K/AKT/mTOR pathway to alleviate keloids.

Liu C, Khairullina L, Qin Y, Zhang Y, Xiao Z Stem Cell Res Ther. 2024; 15(1):305.

PMID: 39278919 PMC: 11403874. DOI: 10.1186/s13287-024-03928-5.


Application and progress of new technologies and new materials in the treatment of pathological scar.

Liu Y, Wang S, Yang F, Wang X, Zhang J, Han X Front Chem. 2024; 12:1389399.

PMID: 38752199 PMC: 11094272. DOI: 10.3389/fchem.2024.1389399.


Pharmacotherapy for Keloids and Hypertrophic Scars.

Murakami T, Shigeki S Int J Mol Sci. 2024; 25(9).

PMID: 38731893 PMC: 11083137. DOI: 10.3390/ijms25094674.


Effects of 5-fluorouracil released from different prosthetic meshes on post-operative adhesion formation in rats.

Balas S, Dora D, Erol T, Akyollu B, Korkusuz P, Hamaloglu E North Clin Istanb. 2023; 9(6):565-575.

PMID: 36685624 PMC: 9833384. DOI: 10.14744/nci.2021.45548.


References
1.
Mari W, Alsabri S, Tabal N, Younes S, Sherif A, Simman R . Novel Insights on Understanding of Keloid Scar: Article Review. J Am Coll Clin Wound Spec. 2017; 7(1-3):1-7. PMC: 5197049. DOI: 10.1016/j.jccw.2016.10.001. View

2.
Hochman B, Isoldi F, Furtado F, Ferreira L . New approach to the understanding of keloid: psychoneuroimmune-endocrine aspects. Clin Cosmet Investig Dermatol. 2015; 8:67-73. PMC: 4329995. DOI: 10.2147/CCID.S49195. View

3.
Ehrlich H, Desmouliere A, Diegelmann R, Cohen I, Compton C, Garner W . Morphological and immunochemical differences between keloid and hypertrophic scar. Am J Pathol. 1994; 145(1):105-13. PMC: 1887298. View

4.
Robles D, Moore E, Draznin M, Berg D . Keloids: pathophysiology and management. Dermatol Online J. 2008; 13(3):9. View

5.
Lv C, Dai H, Xing X, Zhang J . The systematic effects of chitosan on fibroblasts derived from hypertrophic scars and keloids. Indian J Dermatol Venereol Leprol. 2012; 78(4):520. DOI: 10.4103/0378-6323.98098. View